| Joseph A Nicholas, MD | |
|
4448 W. Loomis Rd., Ste 100, Greenfield, WI 53220-4851 | |
| (414) 281-5150 | |
| (414) 281-5767 |
| Full Name | Joseph A Nicholas |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 21 Years |
| Location | 4448 W. Loomis Rd., Greenfield, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528094588 | NPI | - | NPPES |
| 34871200 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 49329-020 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aurora At Home | Milwaukee, WI | Home health agency |
| Aurora St Lukes Medical Center | Milwaukee, WI | Hospital |
| West Allis Memorial Hospital | West allis, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
| Lakeshore Medical Clinic Llc | 7719890730 | 300 |
News Archive
Like power lines in an electrical grid, long wiry projections that grow outward from neurons - structures known as axons - form interconnected communication networks that run from the brain to all parts of the body.
The following quote is attributed to Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
A comprehensive new review of the expanding scope of stimulants available to treat attention deficit hyperactivity disorder serves as a valuable guide to clinicians as they choose from among the many new drug formulations and technologies available to treat this complex disorder.
› Verified 1 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Like power lines in an electrical grid, long wiry projections that grow outward from neurons - structures known as axons - form interconnected communication networks that run from the brain to all parts of the body.
The following quote is attributed to Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
A comprehensive new review of the expanding scope of stimulants available to treat attention deficit hyperactivity disorder serves as a valuable guide to clinicians as they choose from among the many new drug formulations and technologies available to treat this complex disorder.
› Verified 1 days ago
| Entity Name | Lakeshore Medical Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003861188 PECOS PAC ID: 7719890730 Enrollment ID: O20031106000481 |
News Archive
Like power lines in an electrical grid, long wiry projections that grow outward from neurons - structures known as axons - form interconnected communication networks that run from the brain to all parts of the body.
The following quote is attributed to Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
A comprehensive new review of the expanding scope of stimulants available to treat attention deficit hyperactivity disorder serves as a valuable guide to clinicians as they choose from among the many new drug formulations and technologies available to treat this complex disorder.
› Verified 1 days ago
| Entity Name | Aurora Advanced Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265629133 PECOS PAC ID: 3375625833 Enrollment ID: O20080123000694 |
News Archive
Like power lines in an electrical grid, long wiry projections that grow outward from neurons - structures known as axons - form interconnected communication networks that run from the brain to all parts of the body.
The following quote is attributed to Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
A comprehensive new review of the expanding scope of stimulants available to treat attention deficit hyperactivity disorder serves as a valuable guide to clinicians as they choose from among the many new drug formulations and technologies available to treat this complex disorder.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph A Nicholas, MD 100-15th Ave., Ste 180, South Milwaukee, WI 53172-1160 Ph: (414) 768-5430 | Joseph A Nicholas, MD 4448 W. Loomis Rd., Ste 100, Greenfield, WI 53220-4851 Ph: (414) 281-5150 |
News Archive
Like power lines in an electrical grid, long wiry projections that grow outward from neurons - structures known as axons - form interconnected communication networks that run from the brain to all parts of the body.
The following quote is attributed to Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research.
A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.
A comprehensive new review of the expanding scope of stimulants available to treat attention deficit hyperactivity disorder serves as a valuable guide to clinicians as they choose from among the many new drug formulations and technologies available to treat this complex disorder.
› Verified 1 days ago
Abdulrehman Siddiqui, MB BCH BAO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6901 W Edgerton Ave, Greenfield, WI 53220 Phone: 414-325-5244 | |
Dr. Kostandinos Tsoulfas, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4131 W Loomis Rd, #300, Greenfield, WI 53221 Phone: 414-325-7246 Fax: 414-325-3770 | |
Rita E Schulz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4448 W. Loomis Rd., Ste 100, Greenfield, WI 53220 Phone: 414-281-5150 Fax: 414-281-5767 | |
Kathryn M Kiyono, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4448 W Loomis Rd, Ste 100, Greenfield, WI 53220 Phone: 414-281-5150 Fax: 414-281-5767 | |
Yuriy Zamota, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6901 W Edgerton Ave, Greenfield, WI 53220 Phone: 414-325-5244 | |
Venkata K Thota, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4448 W. Loomis Rd., Ste 100, Greenfield, WI 53220 Phone: 414-281-5150 Fax: 414-281-5767 | |
Dr. Garima Chawla, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6901 W Edgerton Ave, Greenfield, WI 53220 Phone: 414-325-5244 |